Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: A preclinical study

Toxicology and Applied Pharmacology

Volumn 177, Issue 2, 2001, Pages 149-156

  Blandizzi, Corrado ^a   De Paolis, Barbara ^a   Colucci, Rocchina ^a   Di Paolo, Antonello ^a   Danesi, Romano ^a   Del Tacca, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Acetylcholinesterase; Blood pressure; Camptothecin; Heart rate; Irinotecan; Vagus nerve

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACETYLCHOLINESTERASE; ANTINEOPLASTIC AGENT; ATROPINE; CAMPTOTHECIN; CHOLINERGIC RECEPTOR; IRINOTECAN; PHYSOSTIGMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BRADYCARDIA; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; HEART RATE; HYPOTENSION; IN VITRO STUDY; MALE; NONHUMAN; RAT; VAGOTOMY;

EID: 0035674850     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.2001.9293     Document Type: Article

References (39)

1. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: Application to plasma pharmacokinetic studies in cancer patients
2. The effects of some autonomic blocking agents on the heart rates of anesthetized and pithed rats
3. B receptors in the regulation of pepsinogen secretion in anesthetized rats
4. Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan
5. Muscarinic receptor agonists and antagonists
6. Tachyphylaxis and sensitization to nicotine-induced tachycardic and pressor effects after nicotine infusions
7. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11)
8. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
9. A new and rapid colorimetric determination of acetylcholinesterase activity
10. Sequence effect of irinotecan and 5-fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy naïve metastatic colorectal cancer patients
11. Attenuation of the baroreceptor reflex by general anesthetic agents in the normotensive rat
12. CPT-11 induced cholinergic effects in cancer patients
13. Vagally mediated reflex and cardiac slowing induced by loperamide in rats
14. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhoea
15. Effect of ascorbate on the contractile response induced by DMPP in guinea-pig ileal longitudinal muscle strip
16. Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats
17. Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat
18. Suitability of urethane anesthesia for physiopharmacological investigations in various systems. 2. Cardiovascular system
19. 3 receptor-mediated Bezold-Jarisch reflex in rats
20. AF-DX 116, a cardio-selective muscarinic antagonist
21. Bradycardia induced by irinotecan: A case report
22. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase
23. Camptothecins: A review of their development and schedules of administration
24. Vagally mediated bradycardic effect of prazosin in anesthetized rats
25. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy
26. Acetylcholinesterase inhibitors: Synthesis and structure-activity relationships of ω-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)-methyl]-aminoalkoxy- heteroaryl derivatives
27. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients
28. Topoisomerase I inhibitors: Review and update
29. Topoisomerase I inhibitors in the treatment of colorectal cancer
30. Phase I and pharmacokinetic trial of weekly CPT-11
31. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-l-piperidino]-carbonyloxy camptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks
32. Cardiovascular and respiratory effects of some anesthetics in the decerebrate rat
33. 14C]butyrate and 4-nitrophenyl butyrate
34. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
35. Anticholinesterase agents
36. Agents acting at the neuromuscular junction and autonomic ganglia
37. Irinotecan in the treatment of colorectal cancer: Clinical overview
38. Methoctramine selectively blocks cardiac muscarinic M2 receptors in vivo
39. Carbamate analogues of (-)-physostigmine: In vitro inhibition of acetyl- and butyrylcholinesterase